Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Immunotherapeutic strategies for high-risk bladder cancer.

Sharma P, Old LJ, Allison JP.

Semin Oncol. 2007 Apr;34(2):165-72. Review.

PMID:
17382800
2.

[Immunotherapy of superficial bladder cancer].

Schmitz-Dräger BJ, Schattka SO, Ebert T.

Urologe A. 1993 Sep;32(5):374-81. Review. German.

PMID:
8212422
3.

Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.

Ardelt PU, Kneitz B, Adam P, Reiss C, Kocot A, Fensterle J, Chen L, Pasqualini R, Arap W, Gerharz EW, Riedmiller H.

Cancer. 2010 Feb 1;116(3):600-9. doi: 10.1002/cncr.24770.

5.

The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.

Yutkin V, Pode D, Pikarsky E, Mandelboim O.

J Urol. 2007 Dec;178(6):2660-4. Epub 2007 Oct 22.

PMID:
17945285
6.

Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.

Demkow T, Alter A, Wiechno P.

Urol Int. 2008;80(1):74-9. doi: 10.1159/000111734. Epub 2008 Jan 18.

PMID:
18204238
7.

Tumor-specific immunotherapy of murine bladder cancer with butanol-extracted antigens and ethylchlorformate polymerized tumor protein.

Rochester MG, Sarosdy MF, Pickett SH, Stogdill BJ, Lamm DL.

J Urol. 1988 Sep;140(3):647-50.

PMID:
3411695
8.

Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.

Zlotta AR, Drowart A, Van Vooren JP, Shekarsarai H, De Cock M, Pirson M, Palfliet K, Jurion F, Simon J, Schulman CC, Huygen K.

J Urol. 1998 Jun;159(6):1885-91.

PMID:
9598481
9.

Therapy of superficial bladder cancer.

Nseyo UO, Lamm DL.

Semin Oncol. 1996 Oct;23(5):598-604. Review.

PMID:
8893870
10.
11.

Predicting bacillus Calmette-Guerin immunotherapy effectiveness.

Griffith TS.

J Urol. 2007 Dec;178(6):2247-8. Epub 2007 Oct 22. No abstract available.

PMID:
17936825
12.

Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.

Ratliff TL, Haaff EO, Catalona WJ.

Clin Immunol Immunopathol. 1986 Aug;40(2):375-9.

PMID:
3487405
13.

High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).

Pansadoro V, Emiliozzi P, depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Sternberg CN.

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):223-7.

PMID:
16767936
14.

[Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].

Otto T, Kälble T.

Urologe A. 1994 Nov;33(6):540-6. Review. German.

PMID:
7817454
15.

Immunotherapy for bladder cancer.

Kamat AM, Lamm DL.

Curr Urol Rep. 2001 Feb;2(1):62-9. Review.

PMID:
12084297
16.

Localized bladder cancer.

Izawa JI, Grossman HB.

Curr Treat Options Oncol. 2000 Dec;1(5):423-32. Review.

PMID:
12057150
17.

[BCG-instillation therapy in superficial bladder tumor--host immune response elicited by local application of BCG].

Hayakawa M, Hatano T, Saito S, Miyazato T, Nakayama M, Igarashi M, Saita H.

Nihon Hinyokika Gakkai Zasshi. 1987 Nov;78(11):1972-81. Japanese. No abstract available.

PMID:
3502480
18.

Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.

Soloway MS, Lee CT, Steinberg GD, Ghandi AA, Jewett MA.

Urol Oncol. 2007 Jul-Aug;25(4):338-40. Review.

PMID:
17628304
19.

Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Patard JJ, Chopin DK, Boccon-Gibod L.

World J Urol. 1993;11(3):165-8. Review.

PMID:
8401636
20.

Reactive arthritis following BCG immunotherapy for bladder carcinoma.

Tinazzi E, Ficarra V, Simeoni S, Peterlana D, Lunardi C.

Clin Rheumatol. 2005 Aug;24(4):425-7. Epub 2005 Jan 20.

PMID:
15660288
Items per page

Supplemental Content

Write to the Help Desk